Table 5. Multivariate analysis of the risk factors for RTDS.
| Variables | Univariate | Multivariate analysis | ||
|---|---|---|---|---|
| P value | Hazard ratio | 95%CI | P value | |
| Resection stage | ||||
| Gender (male vs female) | 0.669 | |||
| Tumor size (>5 vs ≤5cm) | 0.028 | 1.910 | 1.180-3.092 | 0.008 |
| Tumor number (1, 2-3, >3) | 0.504 | |||
| MVI (A vs P) | 0.621 | |||
| Liver cirrhosis (A vs P) |
0.344 | |||
| Differentiation (W, M, L) |
0.744 | |||
| Preoperative AFP (≥400 versus <400 ng/ml) |
0.541 | |||
| Recurrent stage | ||||
| TBIL | 0.134 | |||
| ALT | 0.681 | |||
| AST | 0.507 | |||
| ALB | 0.731 | |||
| CREA | 0.915 | |||
| PT, s | 0.433 | |||
| WBC | 0.614 | |||
| PLT | 0.662 | |||
| Tumor size (>3versus ≤3cm) | 0.531 | |||
| Tumor number(>3 versus ≤3) | <0.001 | 4.004 | 2.040-7.856 | <0.001 |
| Pre-TACE AFP (>8 vs ≤8 ng/ml) | 0.541 | |||
| RFS | 0.447 | |||
| AFP change | <0.001 | 1.650 | 1.174-2.319 | 0.004 |
| Cycles of TACE | <0.001 | 0.899 | 0.821-0.985 | 0.022 |
| mRECIST, DC vs PD |
<0.001 | 0.539 | 0.319-0.912 | 0.021 |
AFP=α-fetoprotein; A=absent; P=present; L=low differentiation; M=moderate differentiation; W =well differentiation; MVI= microvascular invasion; TBIL=total bilirubin; ALT=alanine aminotransferase; AST= aspartate aminotransferase; ALB=albumin; PT=prothrombin time; WBC=white blood cell; PLT=platelet; CI=confidence interval; RFS =recurrence free survival time; TACE=trans-arterial chemoembolization; DC=disease control; PD=disease progression.